• Explore /
  • Poster
  • / The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.

The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.

Abstract Video & Slides Poster

Authors

Elisa Rozeman

Elisa A. Rozeman

Netherlands Cancer Institute, Amsterdam, Netherlands

Elisa A. Rozeman , Judith M. Versluis , Karolina Sikorska , Ruben Lacroix , Lindsay G Grijpink-Ongering , Birthe Heeres , Bart A. Van De Wiel , Petros Dimitriadis , Ayşegül Sari , Stijn Heijmink , Pia Kvistborg , Daan van den Broek , Annegien Broeks , Jan Willem de Groot , Sofie Wilgenhof , Marieke Anne Vollebergh , Johannes V. Van Thienen , John B. A. G. Haanen , Christian U. Blank

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02625337

Citation

J Clin Oncol 38: 2020 (suppl; abstr 10021)

DOI

10.1200/JCO.2020.38.15_suppl.10021

Abstract #

10021

Poster Bd #

370

Abstract Disclosures

Similar Posters

First Author: Elisa A. Rozeman

First Author: Gil Awada

First Author: Manisha H. Shah

First Author: Georgina V. Long